Faron Pharmaceuticals Ltd.
Tykistökatu 6 B, BioCity
Turku
FIN-20520
Tel: 358-2-469-5151
Fax: 358-2-469-5152
Website: http://www.faronpharmaceuticals.com/
52 articles with Faron Pharmaceuticals Ltd.
-
The ASCO Annual Meeting being held in June 3 to 7 will introduce hundreds of posters, abstracts and presentations of cancer studies, preclinical and clinical. BioSpace looks at three presenters.
-
Presentation of Biomarker Analysis at ASCO
5/30/2022
Faron Pharmaceuticals Ltd announces that new biomarker data from patients treated with bexmarilimab as part of the ongoing phase I/II MATINS trial, will be presented at the upcoming American Society of Clinical Oncology 2022 Annual Meeting being held in Chicago, US from June 3 – 7.
-
Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II Bexmarilimab Combination Study in Hematologic Malignancies
5/16/2022
Faron Pharmaceuticals Ltd. announces that both the U.S. Food and Drug Administration and Finnish Medicines Agency have cleared Faron's Investigational New Drug application to begin the Company sponsored BEXMAB study.
-
It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.
-
Faron Pharmaceuticals announced a new analysis that estimates 100% overall survival at 12-months for patients who experienced clinical benefit following treatment with bexmarilimab.
-
Faron Presents Results from Melanoma Cohort of MATINS Trial at 18th Congress of the European Association of Dermato-Oncology (EADO)
4/21/2022
Faron Pharmaceuticals Ltd announces that results from the melanoma cohort in the ongoing phase I/II MATINS trial, will be presented at the 18th Congress of the European Association of Dermato-Oncology, being held in Seville, Spain, April 21 to April 23, 2022.
-
Financial Statement January 1 to December 31 2021
3/25/2022
Faron Pharmaceuticals Ltd announced audited full-year financial results for January 1 to December 31, 2021 and H2 2021 and provided an overview of recent corporate developments.
-
Presentation of Biomarker Data at AACR - Mar 09, 2022
3/9/2022
Faron Pharmaceuticals Ltd announces that an analysis of biomarker data from patients treated with bexmarilimab as part of the ongoing phase I/II MATINS trial, will be presented at the upcoming American Association for Cancer Research Annual Meeting being held in New Orleans, US, from April 8 - 13, 2022.
-
Faron Obtains Debt Funding from IPF Partners
2/28/2022
Faron Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, announces that it has entered into a secured debt agreement with IPF Partners to advance and accelerate its pipeline programs.
-
Faron Updates on Bexmarilimab Development Program
2/23/2022
Faron Pharmaceuticals Ltd announces updated survival data from Phase I/II MATINS study investigating the safety and efficacy of bexmarilimab.
-
Faron Announces R&D Day
2/14/2022
Faron Pharmaceuticals Ltd announces plans to host a virtual R&D Day via webcast on Wednesday, February 23 at 4:00 pm EET, 2:00 pm GMT, 9:00 am EDT.
-
Scientific Reports Publishes INFORAAA Results
2/3/2022
Faron Pharmaceuticals Ltd announces that the multidisciplinary journal Scientific Reports from the Nature Publishing Group published research highlighting results from Faron's Phase II INFORAAA clinical trial.
-
Faron Appoints Marie-Louise Fjällskog as CMO
1/3/2022
Faron Pharmaceuticals Ltd, a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, is pleased to announce the appointment of Marie-Louise Fjällskog, M.D., Ph.D., as Chief Medical Officer of the Company.
-
Faron Announces Topline MATINS Biomarker Analysis
12/9/2021
Faron Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, announces topline biomarker data from the Phase I/II MATINS trial of bexmarilimab.
-
AGC Biologics Partners with Faron Pharmaceuticals to Manufacture Cancer Treatment
5/5/2020
AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization, has been selected to commercially manufacture the treatment Clevegen for partner Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company.
-
Study data monitoring committee has confirmed the good tolerability of Clevegen up to 10mg/kg and confirmed Part I expansion to secure optimal dosing for part II of the MATINS study with advanced solid tumours
10/9/2019
Faron Pharmaceuticals Oy announces feedback from the MATINS study data monitoring committee from the ongoing dose escalation study from part I of the MATINS trial.
-
Poster discussion presentation at ESMO Congress highlights effective immune switch in MATINS patients with advanced solid tumours
9/30/2019
TURKU – FINLAND, 30 September 2019 – Faron Pharmaceuticals Oy, the clinical stage biopharmaceutical company, today announces details from a poster discussion presentation held at the European Society of Medical Oncology 2019 Congress to showcase recent data from its ongoing MATINS study.
-
Faron Pharmaceuticals Ltd: Interim results for the six months ended 30 June 2019
9/23/2019
Faron announces its unaudited interim results for the six months ended 30 June 2019.
-
Faron Pharmaceuticals Oy: Phase II INFORAAA study update
6/26/2019
Faron Pharmaceuticals Oy (AIM: FARN), the clinical stage biopharmaceutical company, today announces interim results from the Phase II INFORAAA study, which examined the effect of Traumakine on mortality (predominantly for Multi-Organ Failure, MOF) and pharmacodynamic biomarkers of surgically operated Ruptured Abdominal Aorta Aneurysm (RAAA) patients.
-
Faron Pharmaceuticals Oy: Final results from YODA study confirm previously reported findings
6/14/2019
Faron Pharmaceuticals Oy (AIM: FARN), the clinical stage biopharmaceutical company, today announces results from its pharmacokinetic/dynamic YODA study examining the administration of concomitant steroids and Traumakine in healthy volunteers.